의약품 수탁제조 및 연구 서비스 시장 규모, 점유율, 동향 분석 리포트 : 서비스별, 지역별, 부문별 예측(2025-2030년)

Pharmaceutical Contract Manufacturing And Research Services Market Growth & Trends:

The global pharmaceutical contract manufacturing and research services market size is anticipated to reach USD 395.23 billion by 2030 and is projected to grow at a CAGR of 6.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Pharmaceutical companies are increasingly leveraging CMOs and CDMOs to avoid substantial capital investments in infrastructure and navigate complex regulatory landscapes. This strategic move allows them to concentrate resources on core competencies like drug discovery and commercialization. The economies of scale achieved by specialized contract organizations further contribute to reduced production costs.

The escalating complexity of drug development, particularly in biologics, biosimilars, HPAPIs, and personalized medicine, necessitates the advanced capabilities and expertise readily available within contract service providers. These organizations often possess cutting-edge technologies such as continuous manufacturing and sophisticated handling systems, which prove vital for efficient and compliant production.

Global health trends, including the rising prevalence of chronic diseases and the demand for affordable generics and biosimilars following patent expirations, are also key growth drivers. The stringent and evolving regulatory environment, coupled with the imperative for faster market entry, incentivizes pharmaceutical companies to utilize the established expertise of CMOs and CDMOs. The strategic geographic shifts towards cost-competitive regions like Asia-Pacific and the emergence of integrated CRO-CDMO models offering comprehensive solutions underscore the dynamic growth of this market.

Pharmaceutical Contract Manufacturing And Research Services Market Report Highlights:

• Based on service, pharmaceutical contract manufacturing services dominated the market with over 60.0% of the total revenue share in 2024, driven by the need for scale and cost efficiency in producing generics, biosimilars, and vaccines.
• Contract manufacturers offer essential capacity, flexibility, and regulatory support, facilitating growth in regions like Asia-Pacific.
• Pharmaceutical contract research services are projected to witness the fastest CAGR of 7.0% over the forecast period.
• Increasing R&D in complex areas and the demand for CROs' specialized expertise offer cost and time savings in global trials through advanced technologies and navigating regulatory complexities.
• The Asia Pacific pharmaceutical contract manufacturing and research services market dominated the global market with a revenue share of more than 40.0% in 2024, supported by increased outsourcing in developing economies like Singapore, China, and India, which have expanding manufacturing capabilities and significant CMO investments.
• In November 2024, Lonza (Switzerland) announced a significant expansion of its bioconjugation capabilities in Visp. This investment includes adding two 1,200L manufacturing suites to meet increasing market demand.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Regional scope
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Service outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Pharmaceutical Contract Manufacturing And Research Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Pharmaceutical Contract Manufacturing And Research Services Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Pharmaceutical Contract Manufacturing And Research Services Market: Service Estimates & Trend Analysis

• 4.1. Service Segment Dashboard
• 4.2. Pharmaceutical Contract Manufacturing And Research Services Market: Service Movement Analysis
• 4.3. Global Pharmaceutical Contract Manufacturing And Research Services Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
• 4.4. Manufacturing
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. API/Bulk Drugs
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Advanced Drug Delivery Formulations
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Packaging
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Finished Dose Formulations
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.2. Solid
      • 4.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.3. Liquid
      • 4.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.4. Semi-solid Formulations
      • 4.4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Research
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Oncology
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Vaccines
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Inflammation & Immunology
    • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.5. Cardiology
    • 4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.6. Neuroscience
    • 4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.7. Others
    • 4.5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical Contract Manufacturing And Research Services Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Dashboard
• 5.2. Regional Market Share Analysis, 2024 & 2030
• 5.3. Pharmaceutical contract manufacturing and research services market by Region: Key Takeaways
• 5.4. North America
  • 5.4.1. U.S.
    • 5.4.1.1. Key country dynamics
    • 5.4.1.2. Regulatory framework/ reimbursement structure
    • 5.4.1.3. Competitive scenario
    • 5.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Canada
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework/ reimbursement structure
    • 5.4.2.3. Competitive scenario
    • 5.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Mexico
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework/ reimbursement structure
    • 5.4.3.3. Competitive scenario
    • 5.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. UK
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework/ reimbursement structure
    • 5.5.1.3. Competitive scenario
    • 5.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Germany
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. France
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.4. Italy
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework/ reimbursement structure
    • 5.5.4.3. Competitive scenario
    • 5.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.5. Spain
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework/ reimbursement structure
    • 5.5.5.3. Competitive scenario
    • 5.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Denmark
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework/ reimbursement structure
    • 5.5.6.3. Competitive scenario
    • 5.5.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.7. Sweden
    • 5.5.7.1. Key country dynamics
    • 5.5.7.2. Regulatory framework/ reimbursement structure
    • 5.5.7.3. Competitive scenario
    • 5.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.8. Norway
    • 5.5.8.1. Key country dynamics
    • 5.5.8.2. Regulatory framework/ reimbursement structure
    • 5.5.8.3. Competitive scenario
    • 5.5.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. China
    • 5.6.1.1. Key country dynamics
    • 5.6.1.2. Regulatory framework/ reimbursement structure
    • 5.6.1.3. Competitive scenario
    • 5.6.1.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.3. India
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Regulatory framework/ reimbursement structure
    • 5.6.3.3. Competitive scenario
    • 5.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.4. Australia
    • 5.6.4.1. Key country dynamics
    • 5.6.4.2. Regulatory framework/ reimbursement structure
    • 5.6.4.3. Competitive scenario
    • 5.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.5. South Korea
    • 5.6.5.1. Key country dynamics
    • 5.6.5.2. Regulatory framework/ reimbursement structure
    • 5.6.5.3. Competitive scenario
    • 5.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.6. Thailand
    • 5.6.6.1. Key country dynamics
    • 5.6.6.2. Regulatory framework/ reimbursement structure
    • 5.6.6.3. Competitive scenario
    • 5.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Brazil
    • 5.7.1.1. Key country dynamics
    • 5.7.1.2. Regulatory framework/ reimbursement structure
    • 5.7.1.3. Competitive scenario
    • 5.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Argentina
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. MEA
  • 5.8.1. South Africa
    • 5.8.1.1. Key country dynamics
    • 5.8.1.2. Regulatory framework/ reimbursement structure
    • 5.8.1.3. Competitive scenario
    • 5.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.2. Saudi Arabia
    • 5.8.2.1. Key country dynamics
    • 5.8.2.2. Regulatory framework/ reimbursement structure
    • 5.8.2.3. Competitive scenario
    • 5.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.3. UAE
    • 5.8.3.1. Key country dynamics
    • 5.8.3.2. Regulatory framework/ reimbursement structure
    • 5.8.3.3. Competitive scenario
    • 5.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.4. Kuwait
    • 5.8.4.1. Key country dynamics
    • 5.8.4.2. Regulatory framework/ reimbursement structure
    • 5.8.4.3. Competitive scenario
    • 5.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. Key company heat map analysis, 2024
• 6.4. Company Profiles
  • 6.4.1. Catalent, Inc (Novo Holdings A/S)
    • 6.4.1.1. Company overview
    • 6.4.1.2. Financial performance
    • 6.4.1.3. Product benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. PPD (Thermo Fisher Scientific Inc.)
    • 6.4.2.1. Company overview
    • 6.4.2.2. Financial performance
    • 6.4.2.3. Product benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. AbbVie Inc.
    • 6.4.3.1. Company overview
    • 6.4.3.2. Financial performance
    • 6.4.3.3. Product benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. Advent International, L.P.
    • 6.4.4.1. Company overview
    • 6.4.4.2. Financial performance
    • 6.4.4.3. Product benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Grifols
    • 6.4.5.1. Company overview
    • 6.4.5.2. Financial performance
    • 6.4.5.3. Product benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. Dalton Pharma Services
    • 6.4.6.1. Company overview
    • 6.4.6.2. Financial performance
    • 6.4.6.3. Product benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Boehringer Ingelheim International GmbH
    • 6.4.7.1. Company overview
    • 6.4.7.2. Financial performance
    • 6.4.7.3. Product benchmarking
    • 6.4.7.4. Strategic initiatives
  • 6.4.8. Lonza
    • 6.4.8.1. Company overview
    • 6.4.8.2. Financial performance
    • 6.4.8.3. Product benchmarking
    • 6.4.8.4. Strategic initiatives